Journal of International Oncology››2017,Vol. 44››Issue (8): 633-637.doi:10.3760/cma.j.issn.1673-422X.2017.08.020

Previous ArticlesNext Articles

Immunotherapy for lymphoma

Wang Jiangtao, Guan Tao, Su Liping

  1. Department of Hematology, Shanxi Provincial Cancer Hospital, Third People′s Hospital of Shanxi Province, Taiyuan 030013, China
  • Online:2017-08-08Published:2017-07-21
  • Contact:Su Liping, Email: sulp2005@sohu.com E-mail:sulp2005@sohu.com

Abstract:At present, immunotherapies for lymphoma are becoming gradually important. Chimeric antigen receptormodified T cells therapy, bispecific antibody and immunecheckpoint inhibitor are considered as breakthrough treatments, each has its own unique mechanism, and more advanced treatments will be developed based on them.

Key words:Lymphoma,Antibody, bispecific,Chimeric antigen receptor-modified T cells,Immunecheckpoint inhibitor